Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development-Reference-Cited by-同舟云学术

Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development

Published:2022-05 Issue:3 Volume:28 Page:196-203
ISSN:1540-336X
Container-title:The Cancer Journal
language:en
Short-container-title:Cancer J

Author:

Laing Abbie J.,Newson Louise,Simon James A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference116 articles.

1. Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: an observational study of clinical outcomes for women in low estrogen states;J Obstet Gynaecol Res,2015

2. Symposium report. Workshop on normal reference ranges for estradiol in postmenopausal women;Menopause,2019

3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause;Menopause,2016

4. Recommendations for the management of postmenopausal vaginal atrophy;Climacteric,2010

5. Prevalence of depression and anxiety in women newly diagnosed with vulvovaginal atrophy and dyspareunia;Menopause,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer;Obstetrics & Gynecology;2023-08-03

2. Current challenges in the pharmacological management of genitourinary syndrome of menopause;Expert Opinion on Pharmacotherapy;2023-01-02